ScottsMiracle-Gro Sees FY23 Mid-Single Digit Percentage Growth In Adj. EBITDA vs 2022

Fiscal 2023 Outlook The Company provided direction for fiscal 2023 that includes the following: Low single-digit percentage growth in adjusted operating income versus fiscal 2022 Mid-single digit percentage

Fiscal 2023 Outlook

The Company provided direction for fiscal 2023 that includes the following:

  • Low single-digit percentage growth in adjusted operating income versus fiscal 2022
  • Mid-single digit percentage growth in adjusted EBITDA versus fiscal 2022
  • Interest expense increase of $35 million to $40 million
  • Effective tax rate of 25 percent to 26 percent
  • Free cash flow of $1 billion over the next two years

Management will outline its 2023 expectations in more detail during its scheduled conference call with the investment community at 9 a.m. Eastern Time today.

Total
0
Shares
Related Posts
Read More

Initial Phase 1 Dose Escalation Data For ORIC-533 In Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity And Strong Safety Profile Supporting Potential For Combination Development At The 65th American Society Of Hematology Annual Meetin…

Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose

ORIC